Dear Doctor,
Radioligand therapy (RLT) is becoming an important pillar of cancer care globally. However, several challenges faced by nuclear medicine physicians need to be overcome. Nuclear medicine physicians were traditionally involved in diagnostic medicine, with little patient contact. RLT involves directly treating patients which often have various co-morbidities. The therapy itself also presents various complex regulatory challenges in Switzerland, potentially limiting widespread adoption. Finally, there is a need to attract younger physicians to this area of medicine because the current workforce is not big enough to treat all patients in the future. The objective of this event is therefore to train and connect young nuclear medicine physicians interested in RLT.
Come and help us shape the future of cancer care in Switzerland!
We look forward to your attendance.
This year we will be awarding two travel awards to attend the biggest European Medical Oncology (ESMO) and Nuclear Medicine (EANM) Conferences:
EANM 2025 Annual Congress, October 4th to 8th, Barcelona, Spain
ESMO Congress 2025, October 17th to 21st, Berlin, Germany
What can you expect from the award?
Mentorship
Travel, accommodation and registration fees*
*while adhering to 33% co-payment rule as outlined in Swiss Ordinance VITH
You must fulfill at least 2 of the following criteria:
Have a nuclear medicine FMH title
Be an experienced speaker involved in previous events
Have published research in RLT/nuclear medicine
Have been an investigator on clinical trials
Have treated a significant number of patients with RLT
Have been involved in local/international guidelines
Are a board member of a medical society
Apply by August 15th
Send your CV, motivation letter & letter of recommendation to gabriela.fosado_wyhooge@novartis.com. The steering committee will select the winners based on academic standing (i.e. the criteria listed above). Applicants should be in residency or have completed their FMH title in the last 5 yrs from the application deadline. Travel award winners will have the privilege of presenting their highlights of ESMO/EANM at this event under the mentorship of Prof Schaefer.
HUG, Geneva
Inselspital, Bern
Onkozentrum, Zürich
CHUV, Lausanne
Bürgerspital Solothurn
Chairs: Prof Dr Schaefer & PD Dr Omlin
PD Dr Paone, EOC Bellinzona
Prof Lorch, USZ Zürich
Chairs: PD Dr Wissmeyer & Prof Lorch
Dr Bianchetto Wolf & Dr Colarusso
Dr Kulgawczuk & PD Dr Omlin
Chairs: Prof Dr Garibotto & PD Dr Omlin
Dr Hayoz
TBD
TBD
sitem-insel
Switzerland
3010 Bern
Novartis Pharma Schweiz AG
Suurstoffi 14
6343 Rotkreuz
Novartis considère que la protection des données personnelles est une question très importante. Par conséquent, Novartis s'efforce de faire preuve de la plus grande transparence dans le traitement des informations personnelles.
Politique de confidentialité | Novartis Suisse
Novartis anerkennt und respektiert die Datenschutzrechte von Einzelpersonen. Um mehr darüber zu erfahren, wie Novartis mit Ihren personenbezogenen Daten umgeht, können Sie die Novartis Datenschutzerklärung unter diesem Link einsehen Datenschutzerklärung | Novartis Schweiz